Patent Issued for Humanetics' BIO 300 Radiation Countermeasure Drug
3/5/2010 8:51:40 AM
MINNEAPOLIS--(BUSINESS WIRE)--In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee.
comments powered by